Predictive Oncology Subsidiary Helomics Executes Next Phase of Agreement with Interpace to Enhance the Diagnosis of Thyroid C...
July 30 2019 - 8:00AM
Predictive Oncology (Nasdaq: POAI) (“Predictive Oncology” or “the
Company”), a company focused on applying artificial intelligence to
personalized medicine and drug discovery, announced today its
Helomics division has executed on an agreement between the company
and Interpace Diagnostics Group, Inc. or Interpace(NASDAQ: IDXG),
collectively known as ‘the Companies”, to build AI-driven models of
thyroid cancer in order to enhance diagnosis of as well as
therapeutic options for thyroid cancer.
This phase of the agreement is expected to leverage
real world clinical data from Interpace’s two thyroid products,
ThyGeNEXT® and ThyraMIR®, coupled with drug response profiles of
thyroid tumors from Helomics’ patient-derived tumor profiling
platform to build D-CHIP AI-driven models of thyroid cancer. The
models will help identify potential druggable targets for treatment
of indolent and aggressive thyroid cancers. Ultimately, the
companies hope to develop a full pipeline of products that work
seamlessly together to both diagnose and assess risk for thyroid
cancer in addition to providing appropriate therapy
recommendations.
“This phase of our ongoing collaboration with
Interpace is a prime example of the capabilities that Helomics can
bring to the diagnostic and pharma sectors. This agreement
continues to demonstrate the applicability of our smart
patient-derived tumor profiling and AI platform to a wide range of
cancers and follows recent partnerships in ovarian cancer and
prostate cancer,” commented Gerald Vardzel, President of
Helomics. “As a Pittsburgh-based subsidiary of Predictive
Oncology, we are particularly pleased to have our most recent
collaborations also be with other members of the Pittsburgh biotech
and research community.”
“The better we understand thyroid cancer, the
better equipped we are to both diagnose and predict treatment
outcomes,” added Jack Stover, CEO of Interpace. “We believe that
the collaboration with Helomics will help enhance both our ability
to diagnose thyroid cancer, and also potentially offer new products
based on the AI-driven models Helomics is building.”
About Predictive Oncology Inc.
Predictive Oncology (Nasdaq: POAI) operates through its three
wholly owned subsidiaries, Helomics, TumorGenesis and Skyline
Medical. Helomics applies artificial intelligence to its rich data
gathered from patient tumors to both personalize cancer therapies
for patients and drive the development of new targeted therapies in
collaborations with pharmaceutical companies. Helomics’
CLIA-certified lab provides clinical testing that assists
oncologists in individualizing patient treatment decisions, by
providing an evidence-based roadmap for therapy. In addition to its
proprietary precision oncology platform, Helomics offers boutique
CRO services that leverage its TruTumor™, patient-derived tumor
models coupled to a wide range of multi-omics assays (genomics,
proteomics and biochemical), and an AI-powered proprietary
bioinformatics platform (D-CHIP) to provide a tailored solution to
its clients’ specific needs. Predictive Oncology’s TumorGenesis
subsidiary is developing a new rapid approach to growing tumors in
the laboratory, which essentially “fools” cancer cells into
thinking they are still growing inside a patient. Its proprietary
Oncology Discovery Technology Platform kits will assist researchers
and clinicians to identify which cancer cells bind to specific
biomarkers. Once the biomarkers are identified they can be used in
TumorGenesis’ Oncology Capture Technology Platforms which isolate
and help categorize an individual patient’s heterogeneous tumor
samples to enable the development of patient specific treatment
options. Helomics and TumorGenesis are focused on ovarian cancer.
Predictive Oncology’s Skyline Medical subsidiary markets its
patented and FDA cleared STREAMWAY System which automates the
collection, measurement and disposal of waste fluid, including
blood, irrigation fluid and others, within a medical facility,
through both domestic and international divisions. The company has
achieved sales in five of the seven continents through both direct
sales and distributor partners. For more information, please visit
www.predictive-oncology.com.
About Interpace Diagnostics, Group, Inc.
Interpace is a leader in enabling personalized medicine,
offering specialized services along the therapeutic value chain
from early diagnosis and prognostic planning to targeted
therapeutic applications. Interpace’s Diagnostic Business is a
fully integrated commercial and bioinformatics business unit that
provides clinically useful molecular diagnostic tests,
bioinformatics and pathology services for evaluating risk of cancer
by leveraging the latest technology in personalized medicine for
improved patient diagnosis and management. Interpace has four
commercialized molecular tests and one test in a clinical
evaluation process (CEP): PancraGEN® for the diagnosis and
prognosis of pancreatic cancer from pancreatic cysts;
ThyGeNEXT® for the diagnosis of thyroid cancer from thyroid
nodules utilizing a next generation sequencing assay;
ThyraMIR® for the diagnosis of thyroid cancer from thyroid
nodules utilizing a proprietary gene expression assay; and
RespriDX® that differentiates lung cancer of primary vs.
metastatic origin. In addition, BarreGEN® for Barrett’s
Esophagus, is currently in a clinical evaluation program whereby we
gather information from physicians using BarreGEN® to assist
us in positioning the product for full launch, partnering and
potentially supporting reimbursement with payers.
Interpace’s Biopharma Business is a market leader in providing
pharmacogenomics testing, genotyping, and biorepository services to
the pharmaceutical and biotech industries. The Biopharma Business
also advances personalized medicine by partnering with
pharmaceutical, academic, and technology leaders to effectively
integrate pharmacogenomics into their drug development and clinical
trial programs with the goals of delivering safer, more effective
drugs to market more quickly, and improving patient care.
For more information, please visit Interpace’s website
at www.interpacediagnostics.com.
Forward-looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, Section
21E of the Securities Exchange Act of 1934 and the Private
Securities Litigation Reform Act of 1995, relating to the Company's
future financial and operating performance. The Companies have
attempted to identify forward looking statements by terminology
including "believes," "estimates," "anticipates," "expects,"
"plans," "projects," "intends," "potential," "may," "could,"
"might," "will," "should," "approximately" or other words that
convey uncertainty of future events or outcomes to identify these
forward-looking statements. These statements are based on current
expectations, assumptions and uncertainties involving judgments
about, among other things, future economic, competitive and market
conditions and future business decisions, all of which are
difficult or impossible to predict accurately and many of which are
beyond the Company's control. These statements also involve known
and unknown risks, uncertainties and other factors that may cause
the Companies’ actual results to be materially different from those
expressed or implied by any forward-looking statement.
Additionally, all forward-looking statements are subject to the
“Risk Factors” detailed from time to time in the Companies’ most
recent Annual Report on Form 10-K and Quarterly Reports on Form
10Q. Because of these and other risks, uncertainties and
assumptions, undue reliance should not be placed on these
forward-looking statements. In addition, these statements speak
only as of the date of this press release and, except as may be
required by law, the Companies undertakes no obligation to revise
or update publicly any forward-looking statements for any
reason.
Contacts (Helomics):Investor Relations
CORE IR
Bret Shapiro
(212) 896-1203
brets@coreir.com
(Interpace)Investor RelationsThe Edison GroupJoe Green(646)
653-7030jgreen@edisonGroup.com
Media Jules Abraham CORE IR julesa@coreir.com 917-885-7378
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Sep 2023 to Sep 2024